— University of Texas spinout is developing world’s first single-molecule protein sequencing platform —
AUSTIN, TX (November 30, 2020) – Research Bridge Partners— a 501 (c) (3) organization that bridges preeminent innovators at mid-continent research universities with the commercialization resources of Silicon Valley—announced a previous investment of seed capital in Erisyon, Inc.
A spin-out from the University of Texas at Austin, Erisyon was co-founded by Professors Edward Marcotte and Eric Anslyn with Jag Swaminathan, Angela Bardo, Zack Simpson and CEO Talli Somekh.
“Erisyon is commercializing the world’s first single molecule protein sequencer to transform the way we detect, treat, and track disease,” said Talli Somekh, CEO of Erisyon. “The technology brings the advantages of next generation DNA sequencing to proteins with the ultimate sensitivity of a single molecule, massive throughput with up to billions of parallel experiments, and absolute quantification of proteins with digital counts of molecules in a sample.”
Research Bridge Partners’ investment will help fund development of core platform technologies, intellectual property, and key applications. Concomitant with the investment, RBP Catalyst Director, Jim Graham, will join the Erisyon Board of Directors.
“We are delighted to be working with Jim and RBP to revolutionize the field of proteomics. RBP’s belief in Erisyon and its commitment to building companies in the middle of the United States is gratifying,” said Somekh.
About Research Bridge Partners
Research Bridge Partners, a 501 (c) (3) organization, enhances the societal and economic impacts of America’s research universities by bridging preeminent innovators at mid-continent institutions with the commercialization resources of Silicon Valley. Founded by Isaac Barchas and Reid Hoffman, Research Bridge Partners uses proprietary data analytics to identify the nation’s leading researchers and translational philanthropy to transform their scientific breakthroughs into investible companies for the benefit of people everywhere.
Erisyon is developing the world’s first single molecule protein sequencer. Inheriting work developed over the course of the past decade at the University of Texas Center for Systems and Synthetic Biology, Erisyon was founded by a group of technologists and entrepreneurs with the ambition to usher in new discoveries that make the world healthier, safer, and more abundant.